Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial

Aptevo Therapeutics Inc.

Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.
ALG.APV-527 Phase 1: 59% (10/17 evaluable) stable disease rate; breast cancer patient stable >12 months.
Company expects multiple data readouts in 2025 and will present at ASH in Q4 2025.
No specific financial results for FY 2024 are disclosed in the provided exhibit text.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.